The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | MCL0208: identification of novel genomic prognostic factors
Simone Ferrero, MD, University of Torino, Torino, Italy, shares an update on the Phase III MCL0208 trial (NCT02354313) of lenalidomide versus observation after induction with rituximab, followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) as first line treatment for patients with mantle cell lymphoma. Dr Ferrero reports that mutations or deletions in TP53 and KMT2D confer poor prognosis of progression-free survival (PFS) and overall survival. Analysis of CD19 cells led to the identification of 351 copy number alterations across samples from 164 patients, four of which had a significant impact on PFS. Dr Ferrero gives an overview of these findings, and describes how they have been incorporated into a prognostic model for risk stratification. This interview took place at the virtual 16th International Conference on Malignant Lymphoma (ICML) 2021.
